| Dr Luvkarnjit Singh, MD | |
|
1411 Woodbourne Rd, Suite A2, Levittown, PA 19057-1540 | |
| (215) 943-2000 | |
| (215) 943-4439 |
| Full Name | Dr Luvkarnjit Singh |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 13 Years |
| Location | 1411 Woodbourne Rd, Levittown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063795284 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD455348 (Pennsylvania) | Primary |
| 207R00000X | Internal Medicine | 25MA09662300 (New Jersey) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Home Health | Springfield, PA | Home health agency |
| Compassus - Greater Philadelphia | Fort washington, PA | Hospice |
| Eleanor's Garden Llc | Phila, PA | Hospice |
| Compassus-greater New Jersey | Willingboro, NJ | Hospice |
| Vitas Health Care Corporation | Blue bell, PA | Hospice |
| St Mary Medical Center | Langhorne, PA | Hospital |
| Robert Wood Johnson University Hospital At Hamilton | Hamilton, NJ | Hospital |
| Attleboro Nursing And Rehab Ce | Langhorne, PA | Nursing home |
| Cranbury Center | Monroe township, NJ | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| First Docs Llc | 1254751456 | 23 |
| Mercer Bucks Medical Associates Pc | 9133024508 | 28 |
| First Docs Llc | 1254751456 | 23 |
| Mercer Bucks Medical Associates Pc | 9133024508 | 28 |
News Archive
OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.
Hazardous alcohol use and depression are among the 10 leading causes of disability and premature death worldwide, according to the World Health Organization. Many low- to middle-income countries have begun to see a steady increase in alcohol use and have entered the early stages of a tobacco epidemic. A study of alcohol use disorders (AUDs), nicotine dependence (ND), and mood and anxiety disorders in the United States and South Korea has found that while AUDs are substantially more common among Americans than South Koreans, alcohol-dependent Americans are significantly more likely to seek treatment.
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.
A multicenter trial looking at whether a single dose of millions of adult, bone-marrow-derived stem cells can aid stroke recovery indicates it's safe and well-tolerated by patients but may not significantly improve their recovery within the first three months, researchers report.
› Verified 9 days ago
| Entity Name | Mercer Bucks Medical Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952485971 PECOS PAC ID: 9133024508 Enrollment ID: O20031201000069 |
News Archive
OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.
Hazardous alcohol use and depression are among the 10 leading causes of disability and premature death worldwide, according to the World Health Organization. Many low- to middle-income countries have begun to see a steady increase in alcohol use and have entered the early stages of a tobacco epidemic. A study of alcohol use disorders (AUDs), nicotine dependence (ND), and mood and anxiety disorders in the United States and South Korea has found that while AUDs are substantially more common among Americans than South Koreans, alcohol-dependent Americans are significantly more likely to seek treatment.
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.
A multicenter trial looking at whether a single dose of millions of adult, bone-marrow-derived stem cells can aid stroke recovery indicates it's safe and well-tolerated by patients but may not significantly improve their recovery within the first three months, researchers report.
› Verified 9 days ago
| Entity Name | Gps Physician Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881109452 PECOS PAC ID: 9739447400 Enrollment ID: O20180123000502 |
News Archive
OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.
Hazardous alcohol use and depression are among the 10 leading causes of disability and premature death worldwide, according to the World Health Organization. Many low- to middle-income countries have begun to see a steady increase in alcohol use and have entered the early stages of a tobacco epidemic. A study of alcohol use disorders (AUDs), nicotine dependence (ND), and mood and anxiety disorders in the United States and South Korea has found that while AUDs are substantially more common among Americans than South Koreans, alcohol-dependent Americans are significantly more likely to seek treatment.
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.
A multicenter trial looking at whether a single dose of millions of adult, bone-marrow-derived stem cells can aid stroke recovery indicates it's safe and well-tolerated by patients but may not significantly improve their recovery within the first three months, researchers report.
› Verified 9 days ago
| Entity Name | First Docs Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154936227 PECOS PAC ID: 1254751456 Enrollment ID: O20201008001780 |
News Archive
OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.
Hazardous alcohol use and depression are among the 10 leading causes of disability and premature death worldwide, according to the World Health Organization. Many low- to middle-income countries have begun to see a steady increase in alcohol use and have entered the early stages of a tobacco epidemic. A study of alcohol use disorders (AUDs), nicotine dependence (ND), and mood and anxiety disorders in the United States and South Korea has found that while AUDs are substantially more common among Americans than South Koreans, alcohol-dependent Americans are significantly more likely to seek treatment.
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.
A multicenter trial looking at whether a single dose of millions of adult, bone-marrow-derived stem cells can aid stroke recovery indicates it's safe and well-tolerated by patients but may not significantly improve their recovery within the first three months, researchers report.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Luvkarnjit Singh, MD 1411 Woodbourne Rd, Suite A2, Levittown, PA 19057-1540 Ph: (215) 943-2000 | Dr Luvkarnjit Singh, MD 1411 Woodbourne Rd, Suite A2, Levittown, PA 19057-1540 Ph: (215) 943-2000 |
News Archive
OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.
Hazardous alcohol use and depression are among the 10 leading causes of disability and premature death worldwide, according to the World Health Organization. Many low- to middle-income countries have begun to see a steady increase in alcohol use and have entered the early stages of a tobacco epidemic. A study of alcohol use disorders (AUDs), nicotine dependence (ND), and mood and anxiety disorders in the United States and South Korea has found that while AUDs are substantially more common among Americans than South Koreans, alcohol-dependent Americans are significantly more likely to seek treatment.
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.
A multicenter trial looking at whether a single dose of millions of adult, bone-marrow-derived stem cells can aid stroke recovery indicates it's safe and well-tolerated by patients but may not significantly improve their recovery within the first three months, researchers report.
› Verified 9 days ago
Dr. Daniel Haimowitz, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Gardenia Rd, Levittown, PA 19057 Phone: 215-943-2222 Fax: 215-943-2223 | |
Elliott B Frank, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1339 Woodbourne Rd, Levittown, PA 19057 Phone: 215-547-3441 | |
Dr. Hossen Mahmud, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1970 Veterans Hwy Apt L11, Levittown, PA 19056 Phone: 508-807-6705 | |
Dr. Sapan Haresh Majmundar, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1411 Woodbourne Rd, Levittown, PA 19057 Phone: 215-943-2000 | |
Dr. Zafar Ali Khan, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1609 Woodbourne Rd, Suite 202b, Levittown, PA 19057 Phone: 215-949-8300 | |
Dr. Angela Frances Jannelli, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1609 Woodbourne Rd, Suite 302b, Levittown, PA 19057 Phone: 215-945-1313 Fax: 215-945-4277 |